Feedback
Settings

Settings

Goto Application

1. WO2023279073 - NEUROTENSIN VARIANTS AND TAGGED PROTEINS COMPRISING NEUROTENSIN OR SORTILIN PROPEPTIDE

Submit observation
PermaLink
Publication Number WO/2023/279073
Publication Date 05.01.2023
International Application No. PCT/US2022/073333
International Filing Date 01.07.2022
IPC
C07K 7/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
C07K 14/72 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
72for hormones
C12N 15/62 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
CPC
C07K 14/72
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
72for hormones
C07K 2319/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
01containing a localisation/targetting motif
06containing a lysosomal/endosomal localisation signal
C07K 2319/74
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
70containing domain for protein-protein interaction
74containing a fusion for binding to a cell surface receptor
C07K 7/083
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
083Neurotensin
C12Y 302/0102
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
YENZYMES
302Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
0102Alpha-glucosidase (3.2.1.20)
Applicants
  • AMICUS THERAPEUTICS, INC. [US]/[US]
Inventors
  • EISENACH, Helen
  • TUSKE, Steven
Agents
  • ALEGRIA, Rory P.
Priority Data
63/217,50001.07.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NEUROTENSIN VARIANTS AND TAGGED PROTEINS COMPRISING NEUROTENSIN OR SORTILIN PROPEPTIDE
(FR) VARIANTS DE NEUROTENSINE ET PROTÉINES MARQUÉES COMPRENANT UN PROPEPTIDE DE NEUROTENSINE OU DE SORTILINE
front page image
Abstract
(EN) The disclosure provides amino acid sequences for neurotensin variants as well as recombinant proteins that contain neurotensin, sortilin propeptide, or variants thereof. The disclosure also provides method of production and method for determining cellular uptake for the recombinant proteins. Gene therapy compositions, pharmaceutical compositions, methods of treatment, and uses of the gene therapy compositions and the recombinant proteins are also disclosed.
(FR) La divulgation concerne des séquences d'acides aminés pour des variants de neurotensine ainsi que des protéines recombinées qui contiennent la neurotensine, le propeptide de la sortiline, ou des variants de ceux-ci. La divulgation concerne également un procédé de production et un procédé de détermination de l'absorption cellulaire pour les protéines recombinées. La divulgation concerne également des compositions de thérapie génique, des compositions pharmaceutiques, des méthodes de traitement et des utilisations des compositions de thérapie génique et des protéines recombinées.
Latest bibliographic data on file with the International Bureau
# -